Supported by educational grants from Genentech and Grifols
TITLE - Inhibitors in Hemophilia: Challenges & Considerations for Healthcare Professionals
TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Hemophilia Pharmacists, Hemophilia Nurses and Nurses
LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Hemophilia Pharmacists, Hemophilia Nurses and Nurses
- Recognize the prevalence of inhibitor development in hemophilia patients and the importance of early identification
- Identify factors that increase a hemophilia patient's risk for development of inhibitors towards factor replacement therapy
- Describe the economic burden and negative impact on quality of life associated with inhibitor development
- Differentiate high responding versus low responding inhibitors
- Identify complications associated with hemophilia and disease progression
- Describe treatment options for patients with inhibitors, including bypassing agents, immune tolerance induction strategies and novel approaches
- Discuss strategies to educate and counsel patients on risk factors for inhibitor formation and management strategies
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Faculty Disclosure: Clarence D. Moore, PharmD, BCPS, BCOP, has no conflicts of interest to disclose in relation to this program. He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.0 hour (0.10CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Knowledge Based Activity
Course release date 4/4/2019
Course expires 4/4/2022
Nursing continuing education credit
Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.0 hour of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Course release date: 4/25/2019
Course expires: 4/25/2021
|Activity Number||Credit Amount||Accreditation Period|
|0535-0000-19-013-H01-P||0.1 CEUs||April 04, 2019 - April 04, 2022|